What You Should Know:
- Kahun, a pioneer in medical knowledge structuring, has introduced a new AI Agent specifically designed for the pharmaceutical industry.
- The AI Agent aims to bridge the gap between medical knowledge and patient context, providing professionals with reliable and accessible drug-related information.
Addressing the Challenges of Pharma-Related Information
The rapid pace of drug development and research has made it increasingly difficult for
Read More
Life Sciences | News, Analysis, Insights - HIT Consultant
Abbott Launches OTC Continuous Glucose Monitor, Lingo
What You Should Know:
- Abbott, a global healthcare company, has announced the U.S. availability of Lingo, a continuous glucose monitoring (CGM) system designed for individuals who want to improve their overall health and wellness.
- Lingo is the first CGM available without a prescription designed for individuals who want to improve their overall health and wellness, regardless of whether they have diabetes.
A Powerful Tool for Health Management
Lingo combines a biosensor
Read More
Genetic Leap, Eli Lilly Partner to Advance RNA Genetic Medicine
What You Should Know:
- Genetic Leap, a pioneering AI-native techbio company, has entered into a strategic research collaboration with Eli Lilly and Company.
- The partnership aims to develop innovative genetic medicine therapeutics using Genetic Leap's cutting-edge RNA-targeted AI platform.
Leveraging AI to Revolutionize RNA Drug Discovery
RNA genetic medicine holds immense promise for addressing a wide range of diseases. By targeting RNA, scientists can potentially
Read More
A Roadmap For Improving Diversity in Cancer Research and Advancing Therapeutic Development
Last month was Cancer Research Awareness Month, which is a great time to celebrate recent findings that the number of adults enrolled in oncology clinical trials has increased – nearly twice as high as past estimates – while also reflecting on the fact that we still have much work to do in overall and proportional clinical trial enrollment. Highlighting the work that still needs to be done, a recent analysis revealed that individuals who participated in new drug trials were not representative of
Read More
FCS Partners with Paradigm to Expand Clinical Trial Access
What You Should Know:
- Florida Cancer Specialists & Research Institute (FCS), a leading provider of comprehensive cancer care, has announced a new partnership with Paradigm Health, a technology platform specializing in clinical trial management.
- The collaboration aims to expand patient access to innovative treatments through more efficient clinical trial recruitment and execution.
A Strategic Partnership for Enhanced Clinical Trial Access
FCS has experienced steady
Read More
Pfizer Launches PfizerForAll: Connecting Patients to Care, Medications & Vaccinations
What You Should Know:
- Pharmaceutical giant Pfizer launches PfizerForAll, a user-friendly platform designed to simplify access to healthcare and wellness management for Americans.
- PfizerForAll addresses a common frustration: the difficulty of navigating the US healthcare system.
- A recent poll by the American Academy of Physician Associates found that 65% of Americans find managing their health overwhelming, and 73% feel the system fails to meet their needs.
Read More
OMNY Health Launches GLP-1 Data Network to Advance Research
What You Should Know:
- OMNY Health, a healthcare ecosystem specializing in data partnerships, today announced the launch of its GLP-1 data network.
- The GLP-1 data network aims to democratize access to healthcare data and empower researchers, clinicians, and life sciences companies to gain valuable insights into GLP-1 therapies.
Addressing Data Gaps in GLP-1 Research
Despite the growing use of GLP-1 agonists, there remains a significant lack of comprehensive data on
Read More
ZBiotics Raises $12M to Expand First Genetically Engineered Probiotics
What You Should Know:
- ZBiotics, the pioneers carving a new category of genetically engineered probiotics, today announced the close of its $12M Series A funding round, led by Spring Tide Capital. The oversubscribed round also includes participation by Access Capital, Seamless Capital, Goat Rodeo Capital, and Seaside Ventures.
- The company will use the funds to meet growing consumer demand, spearhead retail expansion, and drive continued research and development in a new sector,
Read More
Harvard Apparatus Regenerative Technology Secures $5M to Continue Clinical Trial
What You Should Know:
- Harvard Apparatus Regenerative Technology, Inc. (OTCQB: HRGN), a clinical-stage biotechnology company focused on developing organ regeneration technology for severe diseases, has secured approximately $5 million from a new investor through a private placement of shares.
- The funds will be allocated to expedite the clinical development of HRGN's lead product candidate, the HRGN Esophageal Implant (BEI).
- The FDA has approved a phase one and phase two clinical
Read More
Fujitsu Partners with Paradigm for Enhanced Clinical Trials
What You Should Know:
- Fujitsu today announced a series of initiatives aimed at attracting global clinical trials to Japan and addressing the issue of drug loss.
- By partnering with pharmaceutical companies and medical institutions, Fujitsu is leveraging its expertise in technology and healthcare to create a more efficient and effective clinical trial environment.
Key Initiatives
Partnership with Paradigm: Fujitsu has formed a strategic partnership with Paradigm Health,
Read More
